← Patent-cliff monitor small molecule BRIDION SUGAMMADEX SODIUM
Loss of exclusivity June 2028 FDA regulatory exclusivity expiry
Company MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
Drug detail Brand name BRIDION Active ingredient SUGAMMADEX SODIUM Strength EQ 500MG BASE/5ML (EQ 100MG BASE/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval December 2015 Marketing status RX
Listed patents Patent Expires Type RE44733*PED July 2026 — RE44733 January 2026 substance, product
Regulatory exclusivity Code Expires PED June 2028 NPP December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.